Ensayos clínicos

Inclusion Criteria:

• Subject must be ≥ 18 years old.
• Subject must receive a 1st prescription (meaning no known prescription for this drug in the preceding 12 months) for a drug included in Table 1, which is prescribed to them in routine primary care.
• Subject is able and willing to take part and willing to be followed up on for 48 weeks.
• Subject is able to donate saliva.
• Subject has signed informed consent.
• Subject meets requirement for computer access implying computer literacy as measured by active use of the patient portal or their email.

Exclusion Criteria: 

For the investigational arm only:

• Previous (direct-to-consumer, or clinical) pharmacogenomic testing that includes any of the genes included in the Focused Pharmacogenomics Panel.
• Pregnant or lactating.
• Life expectancy estimated to be less than three months as determined by patient receiving hospice care.
• Duration of index drug total treatment length is planned to be less than seven consecutive days.
• Current inpatients.
• Unable to consent to the study.
• Unwilling to take part.
• Subject has no permanent address.
• Subject has no current primary care provider.
• Subject is, in the opinion of the study coordinator after discussion with participating clinician/pharmacist/investigator, not suitable to participate in the study.
• Patient has a diagnosis of stage 4 or 5 chronic kidney disease (CKD) or is receiving dialysis.
• Patients with advanced liver failure (stage Child-Pugh C) or a diagnosis of liver cirrhosis.
• History of a liver transplant or an allogeneic hematopoietic stem cell transplant.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/13/23. Questions regarding updates should be directed to the study team contact.